An observational study in HCC - Hepatocellular Carcinoma, SBRT and TACE, sponsored by Nanfang Hospital, Southern Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
The goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effective and safe for patients with intermediate to advanced hepatocellular carcinoma (HCC) who are not eligible for curative treatment such as surgery or liver transplantation.
This is a single-center, single-arm, retrospective study. All participants included in the analysis will have received the combined treatment regimen.
The main question the study aims to answer is:
Can sequential TACE-SBRT combined with targeted immunotherapy improve the objective response rate (ORR) in patients with intermediate to advanced HCC?
Interventions
Participants in this study have undergone the following treatments:
TACE: a minimally invasive procedure to block the blood supply to the tumor while delivering chemotherapy directly.
SBRT: a highly precise form of radiation therapy targeting the liver tumor. Targeted immunotherapy: systemic treatment that stimulates the immune system to recognize and attack cancer cells.
Participant Population The study includes adult patients diagnosed with intermediate to advanced HCC who were not candidates for curative resection or transplantation.
3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 954 are open to participants now.
This study's enrollment of 17 is below the median of 200 across 754 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with intermediate to advanced hepatocellular carcinoma (HCC) who received sequential TACE-SBRT followed by targeted immunotherapy at a single tertiary medical center. Eligible participants were adults (≥18 years) with unresectable disease not suitable for curative surgery or liver transplantation, with preserved liver function and measurable lesions. The population represents a hospital-based cohort identified from medical records rather than a community sample.
Exclusion Criteria:
Objective Response Rate (ORR) according to mRECIST
Objective response rate (complete response + partial response) assessed by mRECIST based on imaging evaluation.
Time frame: At baseline and every 3 months after treatment initiation, up to study completion (an average of 6months)
Overall Survival (OS)
Time frame: From treatment initiation until death from any cause, up to study completion (an average of 26 months)
Progression-Free Survival (PFS) according to mRECIST
Time from treatment initiation to disease progression or death, assessed by mRECIST.
Time frame: From treatment initiation until disease progression or death, whichever occurs first, up to study completion (an average of 15 months)
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Time frame: From treatment initiation through study completion, up to 18 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University